Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 11—November 2015
CME ACTIVITY - Synopsis

Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA

Dong Sik Jung1, Dimitrios Farmakiotis12, Ying Jiang, Jeffrey J. Tarrand, and Dimitrios P. KontoyiannisComments to Author 
Author affiliations: Dong-A University College of Medicine, Busan, South Korea (D.S. Jung); The University of Texas MD Anderson Cancer Center, Houston, Texas, USA (D.S. Jung, D. Farmakiotis, Y. Jiang, J.J. Tarrand, D.P. Kontoyiannis); Brigham and Women’s Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA (D. Farmakiotis)

Main Article

Table 3

Available susceptibility data for uncommon Candida isolates associated with fungemia among cancer patients, Houston, Texas, USA*

Medication No. (%) cases; ECV, μg/mL
C. guilliermondii, n = 24 (41%)† C. lusitaniae, n = 19 (28%)† C. kefyr, n = 13 (19%)† C. famata, n = 0 (10%)† C. dubliniensis, n = 1 (1%)†
Amphotericin B
No.‡ 24 19 13 7 1
Wild type 24 (100); ≤2 19 (100); ≤2 NE NE 0; ≤2
Non–wild type 0; >2 0; >2 NE NE 1 (100); >2
Fluconazole
No. 24 19 13 7 1
Wild type 20 (83); ≤8 16 (84); ≤2 12 (92); ≤1 NE 1 (100); ≤0.5
Non–wild type 4 (17); >8 3 (16); >2 1 (8); >1 NE 0; >0.5
Voriconazole
No. 17 14 12 7 1
Wild type 13 (76); ≤0.25 13 (93); ≤0.03 10 (83); ≤0.015 NE 1 (100); ≤0.03
Non–wild type 4 (24); >0.25 1 (7); >0.03 2 (17); >0.015 NE 0; >0.03
Itraconazole
No. 24 19 13 7 1
Wild type 21 (88); ≤1 19 (100); ≤0.5 NE NE 1 (100); ≤0.25
Non–wild type 3 (12); >1 0; >0.5 NE NE 0; >0.25
Posaconazole
No. 17 14 12 7 1
Wild type 13 (76); ≤0.5 12 (86); ≤0.12 11 (92); ≤0.25 NE 1 (100); ≤0.12
Non–wild type 4 (24); >0.5 2 (14); >0.12 1 (8); >0.25 NE 0; >0.12
Caspofungin
No. 15 14 11 7 1
Wild type 13 (87); ≤2 11 (79); ≤1 2 (18); ≤0.03 NE 1 (100); ≤0.12
Non–wild type 2 (13); >2‡ 3 (21); >1 9 (82); >0.03 NE 0; >0.12

*Data were available for 57 of 68 isolates (24/28 C. guilliermondii, 0/7 C. famata). ECV, epidemiologic cutoff value (17); NE, not evaluable for susceptibility isolates because there are no defined ECVs for that species.
†Numbers shown are number of isolates evaluable for susceptibility; percentages are percentage of isolates among all isolates.
‡Results were the same by using a clinical breakpoint (MIC >1) or ECV.

Main Article

References
  1. Sipsas  NV, Lewis  RE, Tarrand  JJ, Hachem  R, Rolston  KV, Raad  II, Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52. DOIPubMedGoogle Scholar
  2. Pfaller  MA, Diekema  DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol. 2010;36:1–53. DOIPubMedGoogle Scholar
  3. Marchetti  O, Bille  J, Fluckiger  U, Eggimann  P, Ruef  C, Garbino  J, Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis. 2004;38:311–20 .DOIPubMedGoogle Scholar
  4. Cleveland  AA, Farley  MM, Harrison  LH, Stein  B, Hollick  R, Lockhart  SR, Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011. Clin Infect Dis. 2012;55:1352–61. DOIPubMedGoogle Scholar
  5. Pfaller  MA, Andes  DR, Diekema  DJ, Horn  DL, Reboli  AC, Rotstein  C, Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the prospective antifungal therapy (PATH) Registry 2004–2008. PLoS ONE. 2014;9:e101510. DOIPubMedGoogle Scholar
  6. Marr  KA, Seidel  K, White  TC, Bowden  RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16. DOIPubMedGoogle Scholar
  7. Blanchard  E, Lortholary  O, Boukris-Sitbon  K, Desnos-Ollivier  M, Dromer  F, Guillemot  D, Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France. Antimicrob Agents Chemother. 2011;55:5358–61. DOIPubMedGoogle Scholar
  8. van Burik  JH, Leisenring  W, Myerson  D, Robert  CH, Howard  MS, George  ES, The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplantation recipients with special attention to hepatic candiasis: an autopsy study of 355 patients. Medicine. 1998;77:246–54. DOIPubMedGoogle Scholar
  9. Wingard  JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995;20:115–25 . DOIPubMedGoogle Scholar
  10. Atkinson  BJ, Lewis  RE, Kontoyiannis  DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome. Med Mycol. 2008;46:541–6. DOIPubMedGoogle Scholar
  11. Reuter  CW, Morgan  MA, Bange  FC, Gunzer  F, Eder  M, Hertenstein  B, Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis. 2005;41:1365–6 . DOIPubMedGoogle Scholar
  12. Dufresne  SF, Marr  KA, Sydnor  E, Staab  JF, Karp  JE, Lu  K, Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol. 2014;52:1830–7. DOIPubMedGoogle Scholar
  13. Girmenia  C, Pizzarelli  G, Cristini  F, Barchiesi  F, Spreghini  E, Scalise  G, Candida guilliermondii fungemia in patients with hematologic malignancies. J Clin Microbiol. 2006;44:2458–64 . DOIPubMedGoogle Scholar
  14. Mardani  M, Hanna  HA, Girgawy  E, Raad  I. Nosocomial Candida guilliermondii fungemia in cancer patients. Infect Control Hosp Epidemiol. 2000;21:336–7 . DOIPubMedGoogle Scholar
  15. Johnson  EM. Rare and emerging Candida species. Current Fungal Infection Reports. 2009;3:152–9.
  16. Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th ed. M27–S4. Wayne (PA): The Institute. 2012.
  17. Pfaller  MA, Diekema  DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846–56 PubMed. DOIPubMedGoogle Scholar
  18. Antoniadou  A, Torres  HA, Lewis  RE. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine. 2003;82:309–21. DOIPubMedGoogle Scholar
  19. Freifeld  AG, Bow  EJ, Sepkowitz  KA, Boeckh  MJ, Ito  JI, Mullen  CA, Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–93. DOIPubMedGoogle Scholar
  20. Raad  I, Hanna  H, Boktour  M, Girgawy  E. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis. 2004;38:1119–27. DOIPubMedGoogle Scholar
  21. Falagas  ME, Roussos  N, Vardakas  KZ. Relative frequency of albicans and the various non-albicans Candida spp. among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis. 2010;14:e954–66. DOIPubMedGoogle Scholar
  22. Pfaller  M, Neofytos  D, Diekema  D, Azie  N, Meier-Kriesche  HU, Quan  SP, Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74:323–31 and. DOIPubMedGoogle Scholar
  23. Farmakiotis  D, Tarrand  JJ, Kontoyiannis  DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis. 2014;20:1833–40. DOIPubMedGoogle Scholar
  24. Arendrup  MC, Perlin  DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis. 2014;27:484–92. DOIPubMedGoogle Scholar
  25. Wang  E, Farmakiotis  D, Yang  D, McCue  DA, Kantarjian  HM, Kontoyiannis  DP, The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother. 2015;70:2362–8. DOIPubMedGoogle Scholar
  26. Chen  SC, Marriott  D, Playford  EG, Nguyen  Q, Ellis  D, Meyer  W, Candidemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect. 2009;15:662–9 . DOIPubMedGoogle Scholar
  27. Jung  SI, Shin  JH, Song  JH, Peck  KR, Lee  K, Kim  MN, Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. Med Mycol. 2010;48:669–74 PubMed. DOIPubMedGoogle Scholar
  28. Tang  HJ, Liu  WL, Lin  HL, Lai  CC. Epidemiology and prognostic factors of candidemia in cancer patients. PLoS ONE. 2014;9:e99103 . DOIPubMedGoogle Scholar
  29. Kovacicová  G, Spanik  S, Kunova  A, Trupl  J, Sabo  A, Koren  P, Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis. 2001;33:367–74. DOIPubMedGoogle Scholar
  30. Lai  CC, Chu  CC, Wang  CY, Tsai  HY, Cheng  A, Lee  YC, Association between incidence of candidaemia and consumption of antifungal agents at a medical centre in Taiwan. Int J Antimicrob Agents. 2012;40:349–53 PubMed. DOIPubMedGoogle Scholar
  31. Kontoyiannis  DP, Reddy  BT, Hanna  H, Bodey  GP, Tarrand  J, Raad  I. Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity. Infect Control Hosp Epidemiol. 2002;23:542–5. DOIPubMedGoogle Scholar
  32. Gamaletsou  MN, Walsh  TJ, Zaoutis  T, Pagoni  M, Kotsopoulou  M, Voulgarelis  M, A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7 . DOIPubMedGoogle Scholar
  33. Pfaller  MA, Diekema  DJ, Mendez  M, Kibbler  C, Erzsebet  P, Chang  SC, Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol. 2006;44:3551–6 . DOIPubMedGoogle Scholar
  34. Savini  V, Catavitello  C, Onofrillo  D, Masciarelli  G, Astolfi  D, Balbinot  A, What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast. Mycoses. 2011;54:434–41 PubMed. DOIPubMedGoogle Scholar
  35. Fekkar  A, Dannaoui  E, Meyer  I, Imbert  S, Brossas  JY, Uzunov  M, Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy? Eur J Clin Microbiol Infect Dis. 2014;33:1489–96. DOIPubMedGoogle Scholar
  36. Espinel-Ingroff  A, Arendrup  MC, Pfaller  MA, Bonfietti  LX, Bustamante  B, Canton  E, Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrob Agents Chemother. 2013;57:5836–42. DOIPubMedGoogle Scholar
  37. Shields  RK, Nguyen  MH, Press  EG, Updike  CL, Clancy  CJ. Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and echinocandin resistance. Antimicrob Agents Chemother. 2013;57:6361–5. DOIPubMedGoogle Scholar
  38. Kanafani  ZA, Perfect  JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008;46:120–8 . DOIPubMedGoogle Scholar
  39. Staab  JF, Neofytos  D, Rhee  P, Jimenez-Ortigosa  C, Zhang  SX, Perlin  DS, Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr. Antimicrob Agents Chemother. 2014;58:5421–7 . DOIPubMedGoogle Scholar

Main Article

1These authors contributed equally to this article.

2Current affiliation: Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.

Page created: October 19, 2015
Page updated: October 19, 2015
Page reviewed: October 19, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external